Gram-negative bacteria cause approximately 70% of the infections in intensive 28 care units. A growing number of bacterial isolates responsible for these infections are 29 resistant to currently available antibiotics and to many in development. Most agents 30 under development are modifications of existing drug classes, which only partially 31 overcome existing resistance mechanisms. Therefore, new classes of Gram-negative 32 antibacterials with truly novel modes of action are needed to circumvent these existing 33 resistance mechanisms. We have previously identified a new a way to inhibit an 34 aminoacyl-tRNA synthetase, leucyl-tRNA synthetase (LeuRS), in fungi via the oxaborole 35 tRNA trapping (OBORT) mechanism. Herein, we show how we have modified the 36 OBORT mechanism using a structure-guided approach to develop a new boron-based 37 antibiotic class, the aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA 38 synthetase and have activity against Gram-negative bacteria by largely evading the main 39 efflux mechanisms in Escherichia coli and P. aeruginosa. The lead analogue, AN3365, 40 is active against Gram-negative bacteria, including Enterobacteriaceae bearing NDM-1 41 and KPC carbapenemases as well as Pseudomonas aeruginosa. This novel boron-based 42 antibacterial, AN3365, has good mouse pharmacokinetics and was efficacious against 43
INTRODUCTION 46
The rise in the prevalence of resistance to the frontline Gram-negative 47 7 MIC determination. MIC values were predominately determined using the CLSI broth 134 microdilution method for aerobically and aerobically grown bacteria (23, 24) . MIC values 135
were determined at least twice on separate days with the higher value used to represent 136 the MIC value. 137
Macromolecular synthesis assay. Overnight cultures of E. coli ATCC 25922 were 138 diluted 1000-fold in M9 medium with 0.25% (w/v) yeast extract and allowed to grow to 139 A 600 ~0.3. The culture was incubated at 37°C for 20 minutes with either 2.5 µCi/mL 140 bearing the T252P mutation, into pRE107GM resulted in plasmid pRE107GMP3, which 180 was then conjugated into P. aeruginosa ATCC 27853 by a triparental mating using 181 DH10B bearing the plasmid pRK2013 (27). P. aeruginosa ATCC 27853 transconjugants 182 were selected by their gentamicin and chloramphemicol resistance and their sensitivity to 183 5% (W/V) sucrose was confirmed. These transconjugants were plated out on LB agar 184 containing 5% sucrose (Teknova, CA) and the sucrose-resistant colonies were tested for 185 resistance to AN3365. The leuS gene from the AN3365-resistant sucrose-resistant 186 colonies was sequenced to confirm the presence of the T252P mutation. 187
In vitro cytotoxicity measurements Overnight cultures were treated with the compound 188 and incubated at 37 °C for 24 h with 5% CO 2 . An aliquot of 20 µL/well of Cell Titer 96 curve after an IV dose showed a bi-exponential decline with first-order elimination. 208
Mouse plasma protein binding determination. Compounds were added to 1.5-mL 209 aliquots of mouse plasma and plasma ultrafiltrate to the following concentrations: 1 210 µg/mL and 10 µg/mL, and then incubated in a shaking water-bath at 37 °C for 15 minutes. 211
Both samples were treated similarly and a 0.5-mL aliquot was removed from each tube 212 and added to the filter reservoir of the Microcon ® centrifugal filter devices (Ultracel YM-213 30, MWCO=30K Da, Bedford, MA). The devices were centrifuged at 1000 x g for 10 214 minutes and 100 µL of filtrate was transferred to the 96-well plate and diluted 5-fold. 215
Ten-µL volumes of the samples were injected and analyzed with the LC/MS/MS system. 216
All samples were analysed in duplicate. Quantitation was based on peak areas and all 217 integrations were performed with peak areas using Analyst version 1. to position-3 on AN2679 to gain these interactions. Therefore, the 3-aminomethyl-264 substituted benzoxaborole was synthesized to create AN3017, which had a half-265 maximum inhibitory concentration (IC 50 ) for E. coli LeuRS that was 10-fold more potent 266 than AN2679 ( Figure 1 ). As predicted from the docking analysis, the co-crystal structure 267 of AN3017 ( Figure 3A) showed that its amino group was within hydrogen-bonding 268 distance to Asp342, Asp345 and the carbonyl of Met336 in the amine pocket, which 269 matched the amine interactions observed with Nva2AA. Since only the S-stereoisomer in 270 the AN3017 racemate mixture was observed in the co-crystal structure we isolated both 271 enantiomers by separation of a synthetic intermediate using chiral HPLC followed by 272 removal of the tert-butyl carbamate protecting group to yield AN3334 and AN3376. As Pseudomonas aeruginosa (Table 2) . Furthermore, no significant change in MIC values 278 was observed for a P. aeruginosa strain, which had the genes for three of the major efflux 279 pumps (MexAB-OprM, MexCD-OprJ, MexEF-oprN) deleted. Likewise, no change in 280 MIC values was observed for a strain of E. coli when the efflux-related tolC gene was 281 disrupted by a Tn10 insertion (Table 2) . 282
Additional tRNA interactions improve activity. Although AN3334 was efficacious in a 283 neutropenic mouse infection models of E. coli and P. aeruginosa (Fig. S1 ), it lacked in 284 vitro activity against Proteus mirabilis and Acinetobacter baumannii (Table 2) . Figure 3C ). Although we 299 added both the 3-aminomethyl and tRNA interactions, the IC 50 of AN3213 for the E. coli 300 enzyme was only 4-fold better than AN3016 and AN3017 (Figure 1 ). Since we have 301 previously shown that tavaborole was a slow-tight binding inhibitor with Saccharomyces 302 cerevisiae LeuRS (12), we tested whether these inhibitors had similar kinetics with E. 303 coli LeuRS. We preincubated the E. coli LeuRS enzyme with tRNA and compound for 304 different periods of time ( Table 3 ) and found that the IC 50 for AN2679 and AN3016 did 305 not change with increasing pre-incubation times. However, the IC 50 for AN3334 and 306 AN3213 significantly improved with prolonged pre-incubation and after pre-incubating 307 AN3213 with LeuRS and tRNA for 60 minutes its IC 50 value was greater than 10-fold 308 better than for AN3016 (Table 3) . To corroborate these data, we determined the 309 reactivation rates by measuring the time it took for E. coli LeuRS to recover its activity 310 after dilution of the LeuRS-tRNA-compound inhibitor complex. It took 963 minutes for 311 half of the LeuRS activity to recover after exposure with AN3213, whereas it took only 312 360 minutes with AN3334 (Table 3) . Therefore as predicted from the x-ray co-crystal 313 structure the addition of the 7-O-propanol substitution to the 3-aminomethyl 314 benzoxaborole contributed to the biochemical potency. 315
In order to obtain the active enantiomer of AN3213, a synthetic intermediate was 316 subjected to chiral HPLC separation, which led to the purification of AN3365 and 317 AN3377 (Figure 1) . AN3365 was the active enantiomer and was 150-fold more potent 318 than AN3377 against the E. coli LeuRS enzyme with an IC 50 of 0.31 µM (Figure 1 ).bacterial specificity of the lead compound. AN3365 had no activity against the yeasts, 321
Candida glabrata ATCC 90030 and C. albicans ATCC 90028, with MIC values of >64 322 µg/mL, and it had poor activity versus a human hepatocellular carcinoma cell line 323 (HepG2) and human cytoplasmic LeuRS with IC 50 values of >500 µM and 185 µM, 324
respectively. When AN3365 was tested against a screening panel of E. coli, K. 325 pneumoniae, E. cloacae and P. aeruginosa we observed MIC values ranging from 0.5 -4 326 μg/mL (Table 2) . MIC values against the efflux-deficient bacteria, E. coli tolC::Tn10 327 and P. aeruginosa (ΔmexAB-oprM ΔmexCD-oprJ ΔmexEF-oprN) were not significantly 328 different from the wild-type strains, which suggests that AN3365 is not notably affected 329 by these efflux mechanisms in E. coli and P. aeruginosa (Table 2) . 330
To confirm that AN3365 specifically inhibited protein synthesis, we determined 331 its effect on the major biosynthetic pathways in E. coli ATCC 25922. The half-maximal 332 effective concentration (EC 50 ) for protein synthesis inhibition was within error of its MIC 333 in minimal M9 medium plus 0.25% (w/v) yeast extract, which we used to facilitate 334 incorporation of 14 C-leucine into protein (Table 4) . This behaviour was similar to the 335 effect that was observed with the protein synthesis inhibitor, tetracycline, but was very 336 different from that observed with antibiotics that have other primary targets, namely 337 rifampicin, ciprofloxacin and triclosan (Table 4 ). These data confirm that the observed 338 antibacterial activity of AN3365 is due to selective inhibition of protein biosynthesis. 339 
Downloaded from
Enterobacteriaceae, as well as16 isolates producing the metallo-β-lactamase NDM-1 344 (Table 5 ). AN3365 retained activity against these MDR isolates, for example with an 345 MIC of 2 µg/mL for the fluoroquinolone-, carbapenem-and polymyxin B-resistant 346 isolate A. baumannii BAA-1605 (Table S1 ). No loss of activity was observed for any 347 members of a panel of 11 P. aeruginosa including isolates with metallo-β-lactamases, 348
AmpC over-expression or a mutation in the porin gene oprD (Table S2) . MIC values for 349
19 Enterobacteriaceae isolates and 16 additional isolates with the NDM-1 enzyme all fell 350 within a narrow MIC range from 0.5 to 2 μg/mL (Table 5 ) and no significant resistance 351 was observed even for an Enterobacteriaceae isolate with outer membrane permeability 352 mutations (Table S3 ). This was not the case for the standard antibiotics, ciprofloxacin, 353 levofloxacin, ceftazidime, meropenem, polymyxin B and tigecycline or tobramycin, 354 which were all compromised (Tables 5). However, testing of larger collections of isolates 355 will be necessary to fully confirm the spectrum and antibacterial activity of AN3365. 356 AN3365 was also tested against single isolates of a wider set of bacteria, revealing 357 activity against the Gram-negative anaerobe Bacteroides fragilis and some Gram-positive 358 bacteria (Table 6) . 359
In vivo efficacy against Gram-negative bacterial infections. The pharmacokinetics of 360 AN3365 were determined in mice to ensure that plasma levels were sufficient to perform 361 in vivo efficacy studies. When AN3365 was dosed SC at 30 mg/kg it achieved plasma 362 exposures with an AUC last of 12.1 h.μg/mL and a C max of 8.4 μg/mL (Table 7) Figure 4A ). Predictably, AN3365 was more effective than tobramycin 367 against an aminoglycoside-resistant strain of E. coli, ANA 589, which also produced an 368 extended-spectrum β-lactamase ( Figure 4B ). AN3365 demonstrated similar efficacy to 369 tobramycin when administered SC against P. aeruginosa ATCC 27853 ( Figure 4C) . 370
Although AN3365 is only 21% orally bioavailable in mice (Table 7) , we decided to test 371 its oral efficacy against P. aeruginosa 1161949 in a 4-day immunocompetent murine 372 thigh infection model. When AN3365 was dosed at 75 mg/kg BID it gave a 1.6 log 10 373 CFU reduction from the 1 hour control, while 300 mg/kg BID gave more than a 3 log 10 374 CFU reduction from the 1 hour control ( Figure 4D ). 375
Kinetics of in vitro activity. Aminoacyl-tRNA synthetase inhibitors are bacteriostatic 376 agents (28), thus the bacteriostatic activity of AN3365 with E. coli ATCC 25922 was to 377 be expected ( Figure 5A ). However, the kinetics with P. aeruginosa ATCC 27853 were 378 very different, as the number of colonies dropped by 1.5 log 10 CFU/mL and 3.1 log 10 379 CFU/mL over 24-hours when exposed to 4-fold MIC and 10-fold MIC, respectively 380 ( Figure 5B ). Testing of additional P. aeruginosa isolates will be necessary to determine if 381 this is a species-or strain-specific effect. 382
Anti-pseudomonal mechanism of action. All previous AARS inhibitors are 383 bacteriostatic agents (28, 29) and they inhibit AARS enzymes by binding to the synthetic 384 active site, whereas the aminomethylbenzoxaboroles block tRNA aminoacylation by 385 trapping the tRNA in the editing conformation. Since the levels of the respective AARS 386 and their cognate tRNA are tightly regulated to avoid mischarging (30), it is plausible thatobserved against P. aeruginosa ATCC 27853 at 10-fold the MIC could be due to off-390 target activity. Therefore, we sought to confirm the specificity of AN3365's mechanism 391 of action using a genetic approach. To this end, we selected for AN3365-resistant 392 mutants of P. aeruginosa ATCC 27853 at 4-fold and 10-fold its MIC value on Mueller-393
Hinton agar (MHA) and obtained single-step resistance frequencies of 1.2 x 10 -7 and 4.8x 394
10
-8 , respectively (Table 8 ). These resistance frequencies were comparable to those 395 obtained with E. coli and K. pneumoniae isolates (Table 9 ). Also the frequency of 396 resistance was not that different from those published for fosfomycin with E. coli (31) 397 and tigecycline with K. pneumoniae (32). However, resistance frequency is still on the 398 high side, therefore a potential risk for development of AN3365. 399
Although the AN3365-resistant mutants of P. aeruginosa ATCC 27853 had MIC 400 values for AN3365 of 32 µg/mL and greater, these mutants did not show any changes in 401 MIC values for any of the comparators, for example ciprofloxacin, ceftazidime, 402 gentamicin, tobramycin or polymyxin B. To determine if the resistance mutation resided 403 in the gene for LeuRS we picked ten resistant colonies and sequenced leuS. All ten 404 mutants bore a mutation in the editing active site of LeuRS; five had a missense mutation 405 that would result in a Thr256Pro change, whereas four had a Val342Met change and one 406 had a Thr252Pro change. 407
Mutations in the editing active site confer norvaline sensitivity. Since these mutations 408 resided in the editing active site of LeuRS, we decided to test whether they conferred 409 sensitivity to a close analogue of leucine. Although LeuRS can aminoacylate tRNA and Thr252Pro mutants compared with >64 µg/mL for the parental strain P. aeruginosa 415 ATCC 27853. Since these mutants were sensitive to norvaline, it is likely they are 416 editing-defective (22). This acute sensitivity to norvaline might explain why the editing 417 activity is maintained in most organisms, for example when glucose grown E. coli are 418 subjected to downshifts in oxygen tension they produce millimolar amounts of norvaline 419 (33). As for human pathogens it is unclear how much selective pressure norvaline, which 420 is a natural human metabolite (34), exerts to maintain editing function. However, in some 421 circumstances editing function can be dispensed with where the ratio of leucine over 422 noncognate amino acids can be maintained for example the organelles, the mammalian 423 mitochondria (35) and the malarial apicoplast (36), and MHB where the leucine 424 concentration is approximately 6 mM, which is at least 30-fold higher than the normal 425 human physiological level of 56-203 µM (37). So far the only free living cell that has 426 been convincingly shown to have totally lost their LeuRS editing function is Mycoplasma 427 mobile (38). 428 AN3365 is on-target in P. aeruginosa. In order to confirm that a mutation in leuS 429 confers resistance to AN3365, we re-introduced the Thr252Pro mutation into P. 430 aeruginosa ATCC 27853 using a sacB-mediated allelic replacement method (25). 431 AN3365 and norvaline MIC values for P. aeruginosa ATCC 27853 bearing this mutation 432 were >64 and 0.25 µg/mL, respectively. We conclude that mutations in leuS do confer 433 resistance to AN3365; therefore the slow bactericidal activity observed at 10-fold MIC in 434 this strain of P. aeruginosa is most likely due to on-target inhibition of LeuRS. 10-fold MIC ~10 The IC 50 values were determined by preincubating the compounds with crude E. coli 631 tRNA, E. coli LeuRS enzyme, and 14 C-leucine for 20 minutes, before adding ATP to start 632 the reaction. All reactions were performed in triplicate and the mean values were used to 633 determine an IC 50 using Prism 4 (Graphpad). AN3334 is also known as ABX. 634 
